ESMO 2017: Adjuvant nivolumab superior to ipilimumab in surgically resected stage III/IV melanoma

Adjuvant nivolumab is superior to standard of care ipilimumab in patients with surgically resected stage III/IV melanoma who are at high risk of relapse, according to late-breaking results from the CheckMate 238 trial presented today at the ESMO 2017...

from # All Medicine by Alexandros G. Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2fcwuWo
via IFTTT